terodiline

Terodiline is a small molecule antispasmodic drug formerly used in urology to treat urinary incontinence and detrusor instability syndrome. It acts primarily by relaxing smooth muscle in the bladder, reducing abnormal contractions and lowering bladder tone. The mechanism of action involves both anticholinergic (antimuscarinic) activity and calcium channel antagonism. Terodiline was first approved in 1986 and marketed under the brand name Micturin for urge incontinence and related conditions. However, it was withdrawn worldwide by 1991 due to its association with serious cardiac arrhythmias (notably torsades de pointes), which were linked to blockade of IKr (Kv11.1/hERG) potassium channels—an effect particularly associated with the R-enantiomer of the drug[1][2][4][5][6]. Terodiline was never marketed in the United States but saw use mainly in Europe and Japan before its withdrawal due to cardiotoxicity concerns[5]. Its development history includes initial investigation as an antianginal agent before repurposing for urological indications[6]. The drug is racemic; enantioselective toxicity studies identified that QT prolongation risk is associated with the R-enantiomer.

Brand names

Micturin

Other names

terodilineTerodilinaTerodilinumN-tert-butyl-4,4-diphenylbutan-2-amineN-tert-butyl-1-methyl-3,3-diphenylpropylamine15793-40-5